Business
Go Epic Health to Begin Next Round of Clinical Studies for Cholesterade®
Go Epic Health to Begin Next Round of Clinical Studies for Cholesterade®.
About this update from Leone Asset Management, Inc.
[{"type":"text","content":"\n\n Leone Asset Management announces that their subsidiary Go Epic Health is beginning their next clinical study for Cholesterade®\n St. Petersburg, FL, March 21, 2018 (GLOBE NEWSWIRE) -- James Price, CEO of Go Epic Health, stated, “We are extremely excited to begin the next round of clinical studies on Cholesterade®.  When Dr. Cade first created the product he conducted case studies at the University of Florida and had amazing results in the study.  Recently, Dr. Richard Goldfarb conducted a proof of concept study to once again prove the efficacy of Cholesterade® on lowering cholesterol and also experienced amazing and similar results as Dr. Cade. The next round of studies will be a much larger scale as well as being conducted in a multi-center program.” The research study is to validate the use of Cholesterade® to improve lipid profiles of individuals and examine the cardiovascular benefits of this reduction in lipids. The research study will involve the use of human subjects and thus will need to be in a clinical setting. It will also require prior IRB approval. We intend to use Western IRB for study protocol approval. The study will be conducted in several clinic locations in the Memphis, Tennessee area and will use Cleveland Heart Labs advanced Lipid screen for lab draws and test results. The genesis of this study is based on a previous case study conducted on Cholesterade® namely - Effect of two Dietary Soluble Fibers on Cholesterol and Triglyceride Concentrations in Human Plasma - which showed robust improvement in Lipid profiles of test subjects within 4 weeks of use including LDL, HDL, Total Cholesterol and Triglycerides. We want to build on the results of that study and further explore the medium and long-term effects of Cholesterade® on reduction in lipids and improvement in overall lipid profile as a cardio-protective mechanism for improved clinical outcomes in test subjects. This new proposed study will involve human subjects who will have baseline Total Cholesterol, LDL, HDL, TG and advanced Lipids. These advanced Lipids and Arterial Inflammatory markers have been shown to be elevated in subjects vulnerable to an impending cardiovascular adverse event. In addition to the standard Lipid profile mentioned above and as tested in the previous study, we will be testin...